Alternatives · 3 pages
An alternatives page only means something if it compares the same molecule. Ranking every company under one company's price puts a compounded month beside a brand one and calls the difference a saving, which is the error this whole site exists to correct — so these pages start from the drug, not the number.
Why there are 3 of these and not 53
One per review would be 53 pages, and they would be near-identical. A subject needs 20 measured monthly searches before it gets a route, and at least 3 companies that beat it on its own molecule — otherwise there is no list to write. Both floors fail the build. 41 of the 53 companies we have reviewed publish a month-to-month price at all, which is the pool everything here is drawn from.
Five more companies were measured and none of them got a page. The reasons are worth more than the pages would have been.
| Company | Searches a month | Why there is no page |
|---|---|---|
| TrimRx | 2,000 | The largest search figure behind any page on this site, and the one we cannot write yet: TrimRx's public page moved between two of our reads and its month-to-month figure came from walking the intake, which now screens our research identity out before the plan screen. A page headed “cheaper than TrimRx” rests entirely on TrimRx's own number, so it waits for that number. |
| Hims | 340 | Held in the roster without a published review. There is nothing here to compare against. |
| Noom | 180 | We could not confirm a price for one month with no commitment, and an alternative has to be cheaper than something. |
| Measured | 30 | It clears the demand floor and fails the other one: its cheapest plan is filed as an unnamed GLP-1, because Measured does not say which molecule it is. There is no molecule to match a like-for-like swap against, and the page would have had to compare an unnamed drug with named ones and call the difference a saving. |
| Henry Meds | 30 | Its price sits behind account creation, and we do not open accounts to get a number. |
The cheapest board ranks every company we can price and prints the molecule beside each one, which answers the same question without needing a page per brand. Prices by molecule is the better start if you already know which drug you need, and the head-to-head pages are the ones to use when the choice is already down to two.
Some companies named on these pages pay us a commission. The order is price and the pool is the molecule; neither is for sale. Who pays us · how we review.